| Autor: |
Shedko ED; Federal Budget Institution of Science 'Central Research Institute of Epidemiology' of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance, Moscow, Russia. shedko@cmd.su., Khayrullina GA; Federal Budget Institution of Science 'Central Research Institute of Epidemiology' of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance, Moscow, Russia., Goloveshkina EN; Federal Budget Institution of Science 'Central Research Institute of Epidemiology' of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance, Moscow, Russia., Akimkin VG; Federal Budget Institution of Science 'Central Research Institute of Epidemiology' of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance, Moscow, Russia. |
| Jazyk: |
angličtina |
| Zdroj: |
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology [Eur J Clin Microbiol Infect Dis] 2021 Jul; Vol. 40 (7), pp. 1413-1418. Date of Electronic Publication: 2021 Jan 30. |
| DOI: |
10.1007/s10096-021-04170-0 |
| Abstrakt: |
Mycoplasma genitalium is a widespread sexually transmitted infection (STI) with growing rate of antimicrobials resistance. In our study, 137 vaginal and 131 urethral M. genitalium-positive swabs were sequentially collected through the work of Reference Center for STI during 2019. For prevalence evaluation of macrolide-resistance mutations three commercially available kits were used: AmpliSens® M. genitalium-ML/FQ-Resist-FL (Central Research Institute of Epidemiology, Russia), ResistancePlus® MG (SpeeDx, Australia), and S-DiaMGRes™ (Diagenode, Belgium). Macrolide resistance mutations were detected in 16% (43 of 268) of samples. Diagnostic characteristics were evaluated against Sanger sequencing. For AmpliSens® M. genitalium-ML/FQ-Resist-FL specificity was shown to be 100% (CI 95%, 98.4-100), and sensitivity was 90.7% (CI 95%, 77.9-97.4). ResistancePlus® MG specificity was 100% (CI 95%, 98.3-100), and sensitivity was 92.1% (CI 95%, 78.6-98.3). S-DiaMGRes™ specificity was shown to be 88.6% (CI 95%, 83.9-92.4), and sensitivity was 100% (CI 95%, 84.4-100). Mutations of parC gene region were detected in 14.5% (38 of 268) using AmpliSens® M. genitalium-ML/FQ-Resist-FL with further validation by Sanger sequencing. Of studied samples, 6.3% (17 of 268) contained both antimicrobials of class resistance mutations. Prevalence of macrolide-resistant M. genitalium in Moscow was 21.7% (23 of 106) and of fluoroquinolone-resistant M. genitaliuim was 20.8% (22 of 106). In Moscow region, macrolide-resistant M. genitalium were 12.3% (20 of 162) and 9.9% (16 of 162) of fluoroquinolone-resistant M. genitalium. All three kits can be used both for epidemiological monitoring of M. genitalium presence and mutation prevalence estimation. In Moscow, macrolide- and fluoroquinolone-resistant mutant prevalence increased in 3.9 and 2.7 times in 3 years. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink